Prospective Validation of Pentraxin-3 as a Novel Serum Biomarker to Predict the Risk of Prostate Cancer in Patients Scheduled for Prostate Biopsy.

Ugo Giovanni FalagarioGian Maria Busetto Giuseppe Stefano NettiFrancesca SanguedolceOscar SelvaggioBarbara InfanteElena RanieriGiovanni StalloneGiuseppe CarrieriLuigi Cormio

Published in: Cancers (2021)

Serum PTX3 levels might be of clinical utility in predicting prostate biopsy results. Should our findings be confirmed, this novel reflex test could be used to reduce the number and burden of unnecessary prostate biopsies.

Keyphrases

prostate cancer
radical prostatectomy
end stage renal disease
benign prostatic hyperplasia
ultrasound guided
ejection fraction
newly diagnosed
chronic kidney disease
fine needle aspiration
prognostic factors
peritoneal dialysis
risk factors